Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation - Data from RACE 3

B.O. Nguyen; M. Rienstra; A.H. Hobbelt; J.G.P. Tijssen; M.D. Smit; R.G. Tieleman; B. Geelhoed; D.J. Van Veldhuisen; H.J.G.M. Crijns; I.C. Van Gelder; RACE 3 Investigators

doi:10.1016/j.ahj.2019.12.005

Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation - Data from RACE 3

B.O. Nguyen, M. Rienstra, A.H. Hobbelt, J.G.P. Tijssen, M.D. Smit, R.G. Tieleman, B. Geelhoed, D.J. Van Veldhuisen, H.J.G.M. Crijns, I.C. Van Gelder^*, RACE 3 Investigators

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

Atrial fibrillation (AF) is a progressive disease, and maintenance of sinus rhythm is cumbersome. In this analysis of the Routine versus Aggressive risk factor driven upstream rhythm Control for prevention of Early atrial fibrillation in heart failure (RACE 3) trial we aimed to determine whether optimal treatment of underlying conditions of AF improves maintenance of sinus rhythm in patients with persistent AF and moderate heart failure (HF). Our data showed that optimal treatment of blood pressure, LDL-cholesterol and heart failure was associated with an increase in sinus rhythm maintenance compared to conventional therapy (87% versus 63%, P = .002, respectively).

Original language	English
Pages (from-to)	235-239
Number of pages	5
Journal	American Heart Journal
Volume	226
DOIs	https://doi.org/10.1016/j.ahj.2019.12.005
Publication status	Published - 1 Aug 2020

Keywords

catheter ablation
trial
TRIAL
CATHETER ABLATION

Access to Document

10.1016/j.ahj.2019.12.005

Cite this

Nguyen, B. O., Rienstra, M., Hobbelt, A. H., Tijssen, J. G. P., Smit, M. D., Tieleman, R. G., Geelhoed, B., Van Veldhuisen, D. J., Crijns, H. J. G. M., Van Gelder, I. C., & RACE 3 Investigators (2020). Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation - Data from RACE 3. American Heart Journal, 226, 235-239. https://doi.org/10.1016/j.ahj.2019.12.005

@article{4aac2c1cb91543e0bc70f6f595589d54,

title = "Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation - Data from RACE 3",

abstract = "Atrial fibrillation (AF) is a progressive disease, and maintenance of sinus rhythm is cumbersome. In this analysis of the Routine versus Aggressive risk factor driven upstream rhythm Control for prevention of Early atrial fibrillation in heart failure (RACE 3) trial we aimed to determine whether optimal treatment of underlying conditions of AF improves maintenance of sinus rhythm in patients with persistent AF and moderate heart failure (HF). Our data showed that optimal treatment of blood pressure, LDL-cholesterol and heart failure was associated with an increase in sinus rhythm maintenance compared to conventional therapy (87% versus 63%, P = .002, respectively).",

keywords = "catheter ablation, trial, TRIAL, CATHETER ABLATION",

author = "B.O. Nguyen and M. Rienstra and A.H. Hobbelt and J.G.P. Tijssen and M.D. Smit and R.G. Tieleman and B. Geelhoed and {Van Veldhuisen}, D.J. and H.J.G.M. Crijns and {Van Gelder}, I.C. and {RACE 3 Investigators}",

note = "Funding Information: Funding: The study is supported by the Netherlands Heart Foundation (Grant 2008B035). Unrestricted grants from AstraZeneca, Bayer, Biotronik, Boehringer-Ingelheim, Boston Scientific, Medtronic, Sanofi-Aventis, St Jude Medical paid to the Netherlands Heart Institute. Dr Tieleman reports grants and personal fees from Bayer, Bristol-Myers-Squibb, Pfizer, and Daiichi-Sankyo. All other authors have no competing interests. Funding Information: Funding: The study is supported by the Netherlands Heart Foundation (Grant 2008B035). Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2020",

month = aug,

day = "1",

doi = "10.1016/j.ahj.2019.12.005",

language = "English",

volume = "226",

pages = "235--239",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "MOSBY-ELSEVIER",

}

Nguyen, BO, Rienstra, M, Hobbelt, AH, Tijssen, JGP, Smit, MD, Tieleman, RG, Geelhoed, B, Van Veldhuisen, DJ, Crijns, HJGM, Van Gelder, IC & RACE 3 Investigators 2020, 'Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation - Data from RACE 3', American Heart Journal, vol. 226, pp. 235-239. https://doi.org/10.1016/j.ahj.2019.12.005

TY - JOUR

T1 - Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation - Data from RACE 3

AU - Nguyen, B.O.

AU - Rienstra, M.

AU - Hobbelt, A.H.

AU - Tijssen, J.G.P.

AU - Smit, M.D.

AU - Tieleman, R.G.

AU - Geelhoed, B.

AU - Van Veldhuisen, D.J.

AU - Crijns, H.J.G.M.

AU - Van Gelder, I.C.

AU - RACE 3 Investigators

N1 - Funding Information: Funding: The study is supported by the Netherlands Heart Foundation (Grant 2008B035). Unrestricted grants from AstraZeneca, Bayer, Biotronik, Boehringer-Ingelheim, Boston Scientific, Medtronic, Sanofi-Aventis, St Jude Medical paid to the Netherlands Heart Institute. Dr Tieleman reports grants and personal fees from Bayer, Bristol-Myers-Squibb, Pfizer, and Daiichi-Sankyo. All other authors have no competing interests. Funding Information: Funding: The study is supported by the Netherlands Heart Foundation (Grant 2008B035). Publisher Copyright: © 2019 Elsevier Inc.

PY - 2020/8/1

Y1 - 2020/8/1

N2 - Atrial fibrillation (AF) is a progressive disease, and maintenance of sinus rhythm is cumbersome. In this analysis of the Routine versus Aggressive risk factor driven upstream rhythm Control for prevention of Early atrial fibrillation in heart failure (RACE 3) trial we aimed to determine whether optimal treatment of underlying conditions of AF improves maintenance of sinus rhythm in patients with persistent AF and moderate heart failure (HF). Our data showed that optimal treatment of blood pressure, LDL-cholesterol and heart failure was associated with an increase in sinus rhythm maintenance compared to conventional therapy (87% versus 63%, P = .002, respectively).

AB - Atrial fibrillation (AF) is a progressive disease, and maintenance of sinus rhythm is cumbersome. In this analysis of the Routine versus Aggressive risk factor driven upstream rhythm Control for prevention of Early atrial fibrillation in heart failure (RACE 3) trial we aimed to determine whether optimal treatment of underlying conditions of AF improves maintenance of sinus rhythm in patients with persistent AF and moderate heart failure (HF). Our data showed that optimal treatment of blood pressure, LDL-cholesterol and heart failure was associated with an increase in sinus rhythm maintenance compared to conventional therapy (87% versus 63%, P = .002, respectively).

KW - catheter ablation

KW - trial

KW - TRIAL

KW - CATHETER ABLATION

U2 - 10.1016/j.ahj.2019.12.005

DO - 10.1016/j.ahj.2019.12.005

M3 - Comment/Letter to the editor

C2 - 32067695

SN - 0002-8703

VL - 226

SP - 235

EP - 239

JO - American Heart Journal

JF - American Heart Journal

ER -